

## ALT4

### Product Sheet

Last Updated: 04/06/2021 11:39 AM (EDT)

Author: Darrick Carter



### POC and Institution

POC Name

**Darrick Carter**

POC Title

**Head of Operations**

POC Email

**darrick.carter@pailifesciences.com**

POC Institution

**PAI Life Sciences**

Institution Holds Intellectual Property

**Yes**

Vaccine Ontology Identifier



### Initial Details

Adjuvant Name

**Alt4**

Chemical Nature

• **Combination adjuvant-TLR4 agonist on alhydrogel**

Primary Receptor

• **TLR**

Secondary Receptor

• **TLR4**

Mechanism of Action

**TLR4 and potentially inflammasome**

Immune Profile Induced

**Mixed Th1/Th2**

Drug Master File NIAID Support

**No**

**Yes**

Other Features/Characteristics

Stability Information

**At least 3 months at 2-8 degrees C**

Storage Information

**2-8 degrees C**



### In Vivo Use (Preclinical)

Is there an associated publication?

**No**

PubMedID

Disease Area/Pathogen

**Virus**

Parent Organism

**Severe acute respiratory syndrome-related coronavirus**

Antigen

**Recombinant protein**

Immunization Route

**IM**

Readout

• **Immunogenicity (serology)**

Host Species

**Mouse-C57BL/6**

Were PK/Toxicology studies conducted?

**No**



## Product Grade and Formulation(s)

Product Grade

**Research-grade only**

Formulation(s)

Bedside mixing with antigen possible?

**No**

Also used in combination adjuvant-formulation?

**No**



## Clinical

Not evaluated in humans yet



## Additional Comments